- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.08. | Azitra, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Azitra stock soars after first patient dosed in Phase 1/2 trial | 3 | Investing.com | ||
| 27.08. | Azitra doses first patient in phase 1/2 trial for cancer therapy rash | 2 | Investing.com | ||
| AZITRA Aktie jetzt für 0€ handeln | |||||
| 27.08. | Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash | 199 | PR Newswire | BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 22.08. | Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole-EpicQuest, Zoom, Azitra Stocks In Focus | 4 | Benzinga.com | ||
| 20.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Azitra reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates | 277 | PR Newswire | BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 11.08. | Azitra to implement 1-for-6.66 reverse stock split | 1 | Seeking Alpha | ||
| 11.08. | Azitra, Inc. Announces Reverse Stock Split | 171 | PR Newswire | Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025
BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR)... ► Artikel lesen | |
| 11.08. | Azitra, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.07. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 03.07. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Azitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome | 174 | PR Newswire | Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site
Trial is 50% enrolled... ► Artikel lesen | |
| 14.05. | Azitra GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
| 13.05. | Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates | 178 | PR Newswire | BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 13.05. | Azitra, Inc. - 8-K, Current Report | 11 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,950 | -0,51 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,121 | -2,42 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 18,960 | -5,01 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| QIAGEN | 39,005 | +0,26 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
| EVOTEC | 6,272 | -0,32 % | Kurs von Evotec steigt etwas (5,966 €) | Im Plus liegt zur Stunde die Aktie von Evotec . Das Wertpapier notiert derzeit bei 5,97 Euro. Im deutschen Wertpapierhandel hat sich heute die Aktie von Evotec zwischenzeitlich um 2,54 Prozent verteuert.... ► Artikel lesen | |
| HUMACYTE | 1,860 | +3,91 % | Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4 | ||
| RECURSION PHARMACEUTICALS | 4,910 | -0,41 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| NUVALENT | 76,64 | -5,34 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 82,00 | +0,06 % | Edelmetalle im Check: Rheinmetall | Biontech | Magna - Platin besser als Gold? | Rheinmetall übernimmt die Marinesparte von Lürssen. Der DAX-Konzern stärkt mit dem Kauf seine Position im Marinesektor. Analysten taxieren den Preis auf 1,5 bis 2 Milliarden €. Anleger schicken die... ► Artikel lesen | |
| 89BIO | 14,860 | -0,67 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 6,200 | -2,21 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,090 | -1,72 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
| SUMMIT THERAPEUTICS | 18,860 | -1,92 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| ADMA BIOLOGICS | 15,910 | -1,55 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 49,130 | -3,97 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses |
AZITRA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,86 % bei einem Aktienkurs von 0,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.